Nevirapina Aurobindo (Nevirapine)

Nevirapine, the active ingredient in Nevirapina Aurobindo, is a non‑nucleoside reverse transcriptase inhibitor (NNRTI) presented as a tablet for oral use. It treats HIV‑1 infection in adults and children, helping to suppress viral replication.

GNH USA supplies Nevirapina Aurobindo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable access to antiretroviral therapy for qualified patients. The company adheres to stringent quality standards and offers global distribution to meet the needs of healthcare providers.

Nevirapine is indicated for HIV‑1 infection, targeting the viral replication pathway.

- Adult HIV‑1 infection: Reduces viral load and improves immune function in treatment‑experienced or naïve adults. - Pediatric HIV‑1 infection (≥2 years): Provides viral suppression in children as part of combination antiretroviral therapy. - Prevention of mother‑to‑child transmission of HIV‑1: Used in pregnant women to lower the risk of vertical transmission.

Nevirapine may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Rash: mild to moderate skin eruptions. - Nausea: occasional gastrointestinal upset. - Headache: transient cranial discomfort. - Fatigue: general tiredness. - Insomnia: difficulty sleeping. - Abdominal pain: mild stomach discomfort.

Serious or Rare Side Effects: - Stevens‑Johnson syndrome: severe skin reaction requiring immediate medical attention. - Toxic epidermal necrolysis: life‑threatening skin detachment. - Hepatic failure: marked liver enzyme elevation or liver injury. - Severe hypersensitivity: systemic allergic response. - Neutropenia: significant reduction in white blood cells. - Anemia: decreased red blood cell count.

Before initiating therapy, clinicians should consider several safety measures.

- Monitor liver function: baseline and periodic LFTs due to risk of hepatotoxicity. - Avoid use in patients with known hypersensitivity to nevirapine. - Do not initiate therapy in pregnant women unless benefits outweigh risks. - Assess for concomitant use with strong CYP3A4 inducers which may lower drug exposure. - Educate patients about rash and advise immediate medical evaluation if severe. - Store at ambient temperature: keep in original container, protect from moisture and heat.

Nevirapine interacts with several drug classes, requiring careful management.

Major Interactions (Avoid): - Rifampicin: potent CYP3A4 inducer that markedly reduces nevirapine levels. - Ritonavir-boosted protease inhibitors: can cause unpredictable plasma concentrations. - St. John’s wort: herbal CYP3A4 inducer leading to subtherapeutic exposure.

Moderate Interactions (Monitor Closely): - Other antiretrovirals (e.g., efavirenz): may require dose adjustments. - Warfarin: nevirapine can alter anticoagulant effect, necessitating INR monitoring. - Oral contraceptives: efficacy may be reduced; consider alternative contraception.